|
Jun 20
|
The 5 Most Interesting Analyst Questions From Merck’s Q1 Earnings Call
|
|
Jun 20
|
Why CareTrust, Merck, And Allete Are Winners For Passive Income
|
|
Jun 19
|
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
|
|
Jun 19
|
2 Reasons to Watch MRK and 1 to Stay Cautious
|
|
Jun 18
|
Why the Market Dipped But Merck (MRK) Gained Today
|
|
Jun 18
|
Merck (NYSE:MRK) Begins Phase 3 Trial Of Innovative Prostate Cancer Treatment
|
|
Jun 18
|
American Kidney Fund Launches Kidney Cancer Education Campaign
|
|
Jun 18
|
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
|
|
Jun 18
|
Dividend Growth Remains a Key Priority for Merck
|
|
Jun 17
|
Exiger CMO Kody Gurfein Wins PRNews' Top Women Award
|
|
May 27
|
Merck Announces Third-Quarter 2025 Dividend
|
|
May 23
|
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
|
|
May 23
|
3 Dow Jones Stocks on Our Watchlist
|
|
May 22
|
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
|
|
May 21
|
Merck & Co., Inc. (MRK): A Bull Case Theory
|
|
May 16
|
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
|
|
May 15
|
FDA awards cancer drug approvals to AbbVie and MSD
|
|
May 15
|
FDA approves Merck’s belzutifan for pheochromocytoma or paraganglioma
|
|
May 15
|
Jefferies not seeing significant impact to Merck, Bristol from draft guidance
|
|
May 15
|
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
|